NCT04430192View on ClinicalTrials.gov

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

December 22, 2022

Study Completion Date

August 30, 2025

Conditions
Prostatic Neoplasms
Interventions
DRUG

177Lu-PSMA-617

Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.

Trial Locations (1)

3000

Peter MacCallum Cancer Centre, Melbourne

Sponsors
All Listed Sponsors
collaborator

Movember Foundation

OTHER

collaborator

Medical Research Future Fund

OTHER

collaborator

Endocyte

INDUSTRY

collaborator

E.J. Whitten Foundation Prostate Cancer Research Centre

UNKNOWN

lead

Peter MacCallum Cancer Centre, Australia

OTHER